# Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Source: https://onco.cc/trials/nct06189209/  
OnCo record `nct06189209` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tenalisib in triple-negative breast cancer, run by Rhizen Pharmaceuticals SA, now recruiting.

## Summary

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) is a phase 2 interventional study registered as NCT06189209 by Rhizen Pharmaceuticals SA, with 40 participants planned, started 2024-03-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: Tenalisib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06189209
- Phase: 2
- Setting: A Phase II, Multi-center, Single-arm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K δ/γ, and SIK3 Inhibitor, in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
- Sponsor: Rhizen Pharmaceuticals SA
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06189209: https://clinicaltrials.gov/study/NCT06189209

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Tenalisib](https://onco.cc/drugs/tenalisib/)

---
JSON: https://onco.cc/api/v1/entities/nct06189209.json